FDA Approves Lilly's Foundayo for Weight Loss — South Africa Eyes Access

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Foundayo™ (orforglipron), the first once-daily GLP-1 receptor agonist pill for weight loss that does not require food or water restrictions. The approval marks a significant development in obesity treatment, with the drug already attracting attention in South Africa, where health officials are assessing its potential impact on national obesity rates and healthcare infrastructure.

Foundayo's Breakthrough in Obesity Treatment

Foundayo is the first GLP-1 pill to be approved by the FDA for weight loss, offering a new alternative to injectable medications. Unlike existing treatments, it can be taken at any time of day without dietary restrictions. The drug has shown an average weight loss of 13.8% in clinical trials, according to Eli Lilly, which has positioned it as a game-changer in the fight against obesity.

The approval comes as South Africa grapples with rising obesity rates, particularly in urban areas. According to the South African Medical Research Council, over 60% of women and 30% of men are overweight or obese. Health Minister Joe Phaahla has expressed interest in the drug, stating that it could help address the growing burden on public healthcare systems.

Challenges in Access and Affordability

Despite the approval, accessibility remains a major concern. Foundayo is expected to cost between $1,000 and $1,500 per month in the US, making it prohibitively expensive for many South Africans. The National Department of Health has not yet announced plans for inclusion in the public health system, raising questions about equity in access.

Private healthcare providers in Johannesburg and Cape Town have already begun discussions on incorporating the drug into their offerings. However, experts warn that without government subsidies or partnerships, the drug may only benefit the wealthy. "This is a step forward, but we need to ensure it doesn't widen the health gap," said Dr. Noma Dlamini, a public health specialist at the University of Cape Town.

Implications for Africa's Health Infrastructure

The approval of Foundayo highlights the growing role of biotechnology in addressing chronic diseases across Africa. With obesity rates rising in many regions, the drug could become a critical tool in managing non-communicable diseases (NCDs). However, the continent's healthcare systems, many of which are underfunded and overburdened, may struggle to implement widespread access.

Experts suggest that the key to success lies in public-private partnerships. "If South Africa can negotiate a lower price and integrate Foundayo into its health plans, it could serve as a model for other African nations," said Dr. Sipho Mbeki, an economist at the African Development Bank.

Regulatory and Ethical Considerations

Regulatory bodies across Africa are watching the situation closely. The Southern African Development Community (SADC) has called for coordinated efforts to ensure that new drugs are accessible and affordable. Meanwhile, ethical concerns have emerged about the commercialisation of weight-loss treatments in a continent where food insecurity remains a pressing issue.

Health advocates argue that while Foundayo is a medical breakthrough, it should not overshadow the need for structural changes in nutrition and public health policy. "We need to address the root causes of obesity, not just the symptoms," said Dr. Amina Jalloh, a health policy analyst in Kenya.

Next Steps for South Africa and the Continent

South Africa’s National Essential Medicines List (NEML) committee is expected to review Foundayo in the coming months. If included, the drug could be available through both public and private channels. However, the timeline remains uncertain, with no official announcement yet from the Department of Health.

For now, the focus is on how the continent can balance innovation with equity. With obesity rates set to rise, the approval of Foundayo is a reminder of the urgent need for inclusive health policies. As the global health landscape evolves, Africa must ensure that it is not left behind in the race for medical advancements.

What to watch next: The South African government is expected to announce its stance on Foundayo by the end of the year. If the drug is included in the NEML, it could mark a turning point in the continent's approach to obesity treatment and healthcare access.